Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
5.580
-0.200 (-3.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased
May 13, 2025
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Via
Stocktwits
What to Expect from Altimmune's Earnings
May 12, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
May 05, 2025
Via
Benzinga
What's Going On With Altimmune (ALT) Stock Today?
May 02, 2025
Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.
Via
Benzinga
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
April 30, 2025
Via
The Motley Fool
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
March 03, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
January 23, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
May 13, 2025
Via
Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
April 14, 2025
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Via
Benzinga
8 Analysts Assess Altimmune: What You Need To Know
April 03, 2025
Via
Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 22, 2025
Via
The Motley Fool
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
March 19, 2025
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Via
Stocktwits
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
March 14, 2025
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Decoding 4 Analyst Evaluations For Altimmune
August 22, 2024
Via
Benzinga
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
February 28, 2025
Via
Benzinga
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print
February 27, 2025
The company plans to unveil details at its virtual R&D Day on March 13.
Via
Stocktwits
Exposures
Product Safety
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
January 08, 2025
Via
Benzinga
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
December 20, 2024
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.
Via
Talk Markets
Topics
Stocks / Equities
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
December 04, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
November 13, 2024
Via
Benzinga
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
November 12, 2024
Via
Benzinga
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
November 12, 2024
Via
Benzinga
MarketBeat Week in Review – 11/4 - 11/8
November 09, 2024
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
Via
MarketBeat
Topics
Economy
Government
Exposures
Interest Rates
Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
November 08, 2024
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.
Via
MarketBeat
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
3 Promising Biotech Stocks for the Long-Term: August 2024
August 13, 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
Via
InvestorPlace
The 7 Best Under $10 Stocks to Buy in August 2024
August 11, 2024
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.